Roche Holding AG (SWX: RO)
Switzerland
· Delayed Price · Currency is CHF
304.00
+4.60 (1.54%)
Jan 30, 2025, 5:31 PM CET
Roche Holding AG Revenue
Roche Holding AG had revenue of 30.76B CHF in the half year ending June 30, 2024, a decrease of -9.27%. This brings the company's revenue in the last twelve months to 60.58B, down -3.12% year-over-year. In the year 2023, Roche Holding AG had annual revenue of 60.44B, down -8.16%.
Revenue (ttm)
60.58B
Revenue Growth
-3.12%
P/S Ratio
n/a
Revenue / Employee
584.73K
Employees
103,605
Market Cap
229.25B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
Dec 31, 2019 | 63.75B | 4.25B | 7.15% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 60.58B |
Novartis AG | 42.18B |
Lonza Group AG | 6.70B |
Alcon | 8.25B |
Galderma Group AG | 3.88B |
Straumann Holding AG | 2.54B |
Sonova Holding AG | 3.71B |
Sandoz Group AG | 9.09B |
Roche Holding AG News
- 4 hours ago - Roche Holding AG 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 4 hours ago - Roche Holding AG (RHHBY) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 14 hours ago - We had a strong 2024 and expect momentum to carry into 2025, says Roche CEO - CNBC
- 17 hours ago - Roche Holding Non-GAAP EPS of CHF 18.80, revenue of CHF 60.49B - Seeking Alpha
- 17 hours ago - Roche sees high single-digit core profit growth in 2025 - Reuters
- 17 hours ago - [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth - GlobeNewsWire
- 1 day ago - Change to the Roche Enlarged Corporate Executive Committee - GlobeNewsWire
- 2 days ago - Genentech's Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer - Benzinga